Thermo Fisher Scientific Expands Scientific Advisory Board
News Nov 08, 2012
Thermo Fisher Scientific Inc. announced that Klaus Lindpaintner, MD, MPH, and Edison T. Liu, MD, have joined its Scientific Advisory Board. The board was created in 2010 to formalize the two-way exchange of technological information between the company and representatives from some of the world’s premier centers of health, science and education.
Dr. Lindpaintner became an internal member of the Scientific Advisory Board after recently joining Thermo Fisher in the newly created role of chief scientific officer, analytical technologies. In this highly strategic position, Dr. Lindpaintner will look for opportunities to maximize the impact of the company’s leading portfolio of analytical technologies by assessing the evolving needs of the global life sciences industry.
“I’m pleased to welcome Klaus to our company,” said Marc N. Casper, president and chief executive officer of Thermo Fisher. “In these roles, Klaus will help us accelerate our long-term growth by looking for new opportunities to leverage our unique depth of capabilities in analytical technologies, ensuring a homogenous approach to our R&D efforts and raising Thermo Fisher’s profile as the innovation leader in our industry.”
Dr. Lindpaintner holds Bachelor of Science and Medical Doctorate degrees from the University of Innsbruck in Austria, and a Master of Public Health degree from Harvard University. He served as a Roche Distinguished Scientist and director of the Roche Center for Medical Genomics, as well as global head of molecular medicine policy and external affairs for F. Hoffman-La Roche AG. Most recently, Dr. Lindpaintner was the chief scientific officer and vice president of research and development at Strategic Diagnostics Inc.
His numerous academic appointments include positions at Jiao-Tong University in Shanghai, Stanford University, Harvard University and the University of London. He is also a Fellow of the American College of Physicians and a Fellow of the American College of Medical Genetics.
Dr. Liu, the seventh outside member of the company’s Scientific Advisory Board, is an international leader in cancer biology, genomics, human genetics and molecular biology. He is president and chief executive officer of The Jackson Laboratory, an internationally renowned research center dedicated to discovering the genetic basis for preventing, treating and curing human disease.
“Dr. Liu is a pioneer in cancer research, and his unique experience as both clinician and scientist will bring a valuable perspective to our Scientific Advisory Board,” Casper said. “We’re fortunate to have Dr. Liu as a member of this influential board, which plays an important role in guiding our innovation strategy.”
Dr. Liu also founded the Genome Institute of Singapore in 2001, building it into a major research institute of 27 laboratory groups. From 1996 to 2001, he was scientific director of the National Cancer Institute's Division of Clinical Sciences in Bethesda, Md. Dr. Liu earned his Bachelor of Science degree in chemistry and psychology, as well as his Medical Doctorate, at Stanford University. He served his internship and residency at Washington University's Barnes Hospital in St. Louis, followed by an oncology fellowship at Stanford.
Chinese researchers have developed interfacially polymerized porous polymer particles for low- abundance glycopeptide separation. These polymer particles - with hydrophilic-hydrophobic heterostructured nanopores - can separate low-abundance glycopeptides from complex biological samples with high-abundance background molecules efficiently.